84 related articles for article (PubMed ID: 18364745)
1. NRF-1 is the major transcription factor regulating the expression of the human TOMM34 gene.
Blesa JR; Prieto-Ruiz JA; Abraham BA; Harrison BL; Hegde AA; Hernández-Yago J
Biochem Cell Biol; 2008 Feb; 86(1):46-56. PubMed ID: 18364745
[TBL] [Abstract][Full Text] [Related]
2. Pathway Analysis of ChIP-Seq-Based NRF1 Target Genes Suggests a Logical Hypothesis of their Involvement in the Pathogenesis of Neurodegenerative Diseases.
Satoh J; Kawana N; Yamamoto Y
Gene Regul Syst Bio; 2013; 7():139-52. PubMed ID: 24250222
[TBL] [Abstract][Full Text] [Related]
3. Mismatch Repair-Proficient Colorectal Cancer: Finding the Right TiME to Respond.
Willis JA; Overman MJ; Vilar E
Clin Cancer Res; 2019 Sep; 25(17):5185-5187. PubMed ID: 31263028
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma.
Ma LJ; Feng FL; Dong LQ; Zhang Z; Duan M; Liu LZ; Shi JY; Yang LX; Wang ZC; Zhang S; Ding ZB; Ke AW; Cao Y; Zhang XM; Zhou J; Fan J; Wang XY; Gao Q
Theranostics; 2018; 8(20):5690-5702. PubMed ID: 30555574
[No Abstract] [Full Text] [Related]
5. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
Kao SC; Cheng YY; Williams M; Kirschner MB; Madore J; Lum T; Sarun KH; Linton A; McCaughan B; Klebe S; van Zandwijk N; Scolyer RA; Boyer MJ; Cooper WA; Reid G
J Thorac Oncol; 2017 Sep; 12(9):1421-1433. PubMed ID: 28629895
[TBL] [Abstract][Full Text] [Related]
6. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Le DT; Uram JN; Wang H; Bartlett BR; Kemberling H; Eyring AD; Skora AD; Luber BS; Azad NS; Laheru D; Biedrzycki B; Donehower RC; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Duffy SM; Goldberg RM; de la Chapelle A; Koshiji M; Bhaijee F; Huebner T; Hruban RH; Wood LD; Cuka N; Pardoll DM; Papadopoulos N; Kinzler KW; Zhou S; Cornish TC; Taube JM; Anders RA; Eshleman JR; Vogelstein B; Diaz LA
N Engl J Med; 2015 Jun; 372(26):2509-20. PubMed ID: 26028255
[TBL] [Abstract][Full Text] [Related]
7. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
Fukuoka S; Hara H; Takahashi N; Kojima T; Kawazoe A; Asayama M; Yoshii T; Kotani D; Tamura H; Mikamoto Y; Hirano N; Wakabayashi M; Nomura S; Sato A; Kuwata T; Togashi Y; Nishikawa H; Shitara K
J Clin Oncol; 2020 Jun; 38(18):2053-2061. PubMed ID: 32343640
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
Chalabi M; Fanchi LF; Dijkstra KK; Van den Berg JG; Aalbers AG; Sikorska K; Lopez-Yurda M; Grootscholten C; Beets GL; Snaebjornsson P; Maas M; Mertz M; Veninga V; Bounova G; Broeks A; Beets-Tan RG; de Wijkerslooth TR; van Lent AU; Marsman HA; Nuijten E; Kok NF; Kuiper M; Verbeek WH; Kok M; Van Leerdam ME; Schumacher TN; Voest EE; Haanen JB
Nat Med; 2020 Apr; 26(4):566-576. PubMed ID: 32251400
[TBL] [Abstract][Full Text] [Related]
10. Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway.
Liu C; Yao Z; Wang J; Zhang W; Yang Y; Zhang Y; Qu X; Zhu Y; Zou J; Peng S; Zhao Y; Zhao S; He B; Mi Q; Liu X; Zhang X; Du Q
Cell Death Differ; 2020 Jun; 27(6):1765-1781. PubMed ID: 31802034
[TBL] [Abstract][Full Text] [Related]
11. IL-17 inhibits CXCL9/10-mediated recruitment of CD8
Chen J; Ye X; Pitmon E; Lu M; Wan J; Jellison ER; Adler AJ; Vella AT; Wang K
J Immunother Cancer; 2019 Nov; 7(1):324. PubMed ID: 31775909
[TBL] [Abstract][Full Text] [Related]
12. VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers.
Kim CG; Jang M; Kim Y; Leem G; Kim KH; Lee H; Kim TS; Choi SJ; Kim HD; Han JW; Kwon M; Kim JH; Lee AJ; Nam SK; Bae SJ; Lee SB; Shin SJ; Park SH; Ahn JB; Jung I; Lee KY; Park SH; Kim H; Min BS; Shin EC
Sci Immunol; 2019 Nov; 4(41):. PubMed ID: 31704735
[TBL] [Abstract][Full Text] [Related]
13. IL-17A secreted from lymphatic endothelial cells promotes tumorigenesis by upregulation of PD-L1 in hepatoma stem cells.
Wei Y; Shi D; Liang Z; Liu Y; Li Y; Xing Y; Liu W; Ai Z; Zhuang J; Chen X; Gao Q; Jiang J
J Hepatol; 2019 Dec; 71(6):1206-1215. PubMed ID: 31499129
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-17 is associated with expression of programmed cell death 1 ligand 1 in ovarian carcinoma.
Aotsuka A; Matsumoto Y; Arimoto T; Kawata A; Ogishima J; Taguchi A; Tanikawa M; Sone K; Mori-Uchino M; Tsuruga T; Oda K; Kawana K; Osuga Y; Fujii T
Cancer Sci; 2019 Oct; 110(10):3068-3078. PubMed ID: 31432577
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors.
Llosa NJ; Luber B; Tam AJ; Smith KN; Siegel N; Awan AH; Fan H; Oke T; Zhang J; Domingue J; Engle EL; Roberts CA; Bartlett BR; Aulakh LK; Thompson ED; Taube JM; Durham JN; Sears CL; Le DT; Diaz LA; Pardoll DM; Wang H; Anders RA; Housseau F
Clin Cancer Res; 2019 Sep; 25(17):5250-5259. PubMed ID: 31061070
[TBL] [Abstract][Full Text] [Related]
16. Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry.
Duncan DJ; Scott M; Scorer P; Barker C
PLoS One; 2019; 14(4):e0215393. PubMed ID: 30986253
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in colorectal cancer: rationale, challenges and potential.
Ganesh K; Stadler ZK; Cercek A; Mendelsohn RB; Shia J; Segal NH; Diaz LA
Nat Rev Gastroenterol Hepatol; 2019 Jun; 16(6):361-375. PubMed ID: 30886395
[TBL] [Abstract][Full Text] [Related]
19. IL-17 and colorectal cancer: From carcinogenesis to treatment.
Razi S; Baradaran Noveiry B; Keshavarz-Fathi M; Rezaei N
Cytokine; 2019 Apr; 116():7-12. PubMed ID: 30684916
[TBL] [Abstract][Full Text] [Related]
20. Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
Conroy JM; Pabla S; Nesline MK; Glenn ST; Papanicolau-Sengos A; Burgher B; Andreas J; Giamo V; Wang Y; Lenzo FL; Bshara W; Khalil M; Dy GK; Madden KG; Shirai K; Dragnev K; Tafe LJ; Zhu J; Labriola M; Marin D; McCall SJ; Clarke J; George DJ; Zhang T; Zibelman M; Ghatalia P; Araujo-Fernandez I; de la Cruz-Merino L; Singavi A; George B; MacKinnon AC; Thompson J; Singh R; Jacob R; Kasuganti D; Shah N; Day R; Galluzzi L; Gardner M; Morrison C
J Immunother Cancer; 2019 Jan; 7(1):18. PubMed ID: 30678715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
